scholarly journals Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Jia Li ◽  
Shancheng Ren ◽  
Hai-long Piao ◽  
Fubo Wang ◽  
Peiyuan Yin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lipid Metabolism ◽  
Cholesteryl Oleate ◽  
Potential Biomarker

The correlation between lipid metabolism disorders and the prostate cancer

2020 ◽  
Vol 27 ◽  
Author(s):  
Justyna Dłubek ◽  
Jacek Rysz ◽  
Zbigniew Jabłonowski ◽  
Anna Gluba-Brzózka ◽  
Beata Franczyk
Keyword(s):  
Prostate Cancer ◽  
Fatty Acids ◽  
Lipid Metabolism ◽  
Cancer Progression ◽  
De Novo ◽  
Prostate Gland ◽  
Hdl Cholesterol ◽  
Atp Citrate Lyase ◽  
Male Population ◽  
Lipid Metabolism Disorders

: Prostate cancer is second most common cancer affecting male population all over the world. The existence of a correlation between lipid metabolism disorders and cancer of the prostate gland has been widely known for a long time. According to hypotheses, cholesterol may contribute to prostate cancer progression as a result of its participation as a signalling molecule in prostate growth and differentiation via numerous biologic mechanisms including Akt signalling and de novo steroidogenesis. The results of some studies suggest that increased cholesterol levels may be associated with higher risk of more aggressive course of disease. The aforementioned alterations in the synthesis of fatty acids are a unique feature of cancer and, therefore, it constitutes an attractive target for therapeutic intervention in the treatment of prostate cancer. Pharmacological or gene therapy aimed to reduce the activity of enzymes involved in de novo synthesis of fatty acids, FASN, ACLY (ATP citrate lyase) or SCD-1 (stearoyl-CoA desaturase) in particular, may result in cells growth arrest. Nevertheless, not all cancers are unequivocally associated with hypocholesterolaemia. It cannot be ruled out that the relationship between prostate cancer and lipid disorders is not a direct quantitative correlation between carcinogenesis and the amount of the circulating cholesterol. Perhaps the correspondence is more sophisticated and connected to the distribution of cholesterol fractions, or even sub-fractions of e.g. HDL cholesterol.

scholarly journals YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer

Oncogene ◽  
2021 ◽  
Author(s):  
Hsiu-Chi Lee ◽  
Chien-Hui Ou ◽  
Yun-Chen Huang ◽  
Pei-Chi Hou ◽  
Chad J. Creighton ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lipid Metabolism ◽  
Critical Issue ◽  
Castration Resistant Prostate Cancer ◽  
Cancer Stemness ◽  
New Treatment ◽  
Underlying Mechanisms ◽  
Transcriptional Complex

AbstractMetastatic castration-resistant prostate cancer (mCRPC) is a malignant and lethal disease caused by relapse after androgen-deprivation (ADT) therapy. Since enzalutamide is innovated and approved by US FDA as a new treatment option for mCRPC patients, drug resistance for enzalutamide is a critical issue during clinical usage. Although several underlying mechanisms causing enzalutamide resistance were previously identified, most of them revealed that drug resistant cells are still highly addicted to androgen and AR functions. Due to the numerous physical functions of AR in men, innovated AR-independent therapy might alleviate enzalutamide resistance and prevent production of adverse side effects. Here, we have identified that yes-associated protein 1 (YAP1) is overexpressed in enzalutamide-resistant (EnzaR) cells. Furthermore, enzalutamide-induced YAP1 expression is mediated through the function of chicken ovalbumin upstream promoter transcription factor 2 (COUP-TFII) at the transcriptional and the post-transcriptional levels. Functional analyses reveal that YAP1 positively regulates numerous genes related to cancer stemness and lipid metabolism and interacts with COUP-TFII to form a transcriptional complex. More importantly, YAP1 inhibitor attenuates the growth and cancer stemness of EnzaR cells in vitro and in vivo. Finally, YAP1, COUP-TFII, and miR-21 are detected in the extracellular vesicles (EVs) isolated from EnzaR cells and sera of patients. In addition, treatment with EnzaR-EVs induces the abilities of cancer stemness, lipid metabolism and enzalutamide resistance in its parental cells. Taken together, these results suggest that YAP1 might be a crucial factor involved in the development of enzalutamide resistance and can be an alternative therapeutic target in prostate cancer.

scholarly journals GPR160 is a potential biomarker associated with prostate cancer

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Wanjing Guo ◽  
Junyu Zhang ◽  
Yan Zhou ◽  
Caihong Zhou ◽  
Yunjie Yang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Potential Biomarker

Eukaryotic Elongation Factor 2 (eEF2) is a Potential Biomarker of Prostate Cancer

2017 ◽  
Vol 24 (4) ◽  
pp. 885-890 ◽  
Author(s):  
Xuefeng Zhang ◽  
Linkun Hu ◽  
Mingzhan Du ◽  
Xuedong Wei ◽  
Jun Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Elongation Factor ◽  
Elongation Factor 2 ◽  
Eukaryotic Elongation Factor 2 ◽  
Eukaryotic Elongation Factor ◽  
Potential Biomarker

MiR-145-5p modulates lipid metabolism and M2 macrophage polarization by targeting PAK7 and regulating β-catenin signaling in hyperlipidemia

2021 ◽  
pp. 1-7
Author(s):  
Huijun Chen ◽  
Jing Gao ◽  
Qian Xu ◽  
Dongmei Wan ◽  
Wenji Zhai ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
High Density Lipoprotein ◽  
Macrophage Polarization ◽  
Density Lipoprotein ◽  
High Density ◽  
M2 Macrophage ◽  
Cardiac Tissues ◽  
Potential Biomarker ◽  
Wide Range ◽  
M2 Macrophage Polarization

The present study aims to explore the role of microRNA 145-5p (miR-145-5p) in hyperlipidemia. Using bioinformatics tools and a wide range of function and mechanism assays, we attempted to understand the specific function and potential mechanism of miR-145-5p in hyperlipidemia. A cholesterol-enriched diet induced an increase of serum cholesterol and triacylglycerol but a decrease of serum high-density lipoprotein. MiR-145-5p level was decreased in hyperlipidemia rat models. MiR-145-5p regulated lipid metabolism by antagonizing the alteration of high-density lipoprotein, cholesterol, and triacylglycerol in serum mediated by a cholesterol-enriched diet. In mechanism, miR-145-5p directly bound with p21 protein (RAC1)-activated kinase 7 (PAK7) and negatively regulated mRNA and protein levels of PAK7 in THP-1 cells. Furthermore, miR-145-5p level was negatively associated with PAK7 level in rat cardiac tissues. Finally, overexpression of PAK7 reversed the effects of miR-145-5p on β-catenin activation and M2 macrophages polarization in THP-1 cells. In conclusion, MiR-145-5p modulated lipid metabolism and M2 macrophage polarization by targeting PAK7 and regulating β-catenin signaling in hyperlipidemia, which may provide a potential biomarker for the treatment of hyperlipidemia-induced cardiovascular diseases.

scholarly journals Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer

2017 ◽  
Vol 397 ◽  
pp. 52-60 ◽  
Author(s):  
Jordan O'Malley ◽  
Rahul Kumar ◽  
Andrey N. Kuzmin ◽  
Artem Pliss ◽  
Neelu Yadav ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Raman Microspectroscopy ◽  
Lipid Quantification ◽  
Potential Biomarker

Ellagic Acid Modulates Lipid Metabolism in Prostate Cancer

2004 ◽  
pp. 341-355
Author(s):  
Narayanan Narayanan ◽  
Bhagavathi Narayanan ◽  
Daniel Nixon ◽  
Otto Geoffroy
Keyword(s):  
Prostate Cancer ◽  
Lipid Metabolism ◽  
Ellagic Acid

scholarly journals NMR-Based Metabolomic Profiling of Urine: Evaluation for Application in Prostate Cancer Detection

2019 ◽  
Vol 14 (5) ◽  
pp. 1934578X1984997 ◽  
Author(s):  
Neil MacKinnon ◽  
Wencheng Ge ◽  
Peisong Han ◽  
Javed Siddiqui ◽  
John T. Wei ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
Clinical Test ◽  
H Nmr ◽  
Metabolomic Profiling ◽  
Potential Biomarker ◽  
Noninvasive Biomarker ◽  
Auc Value ◽  
Selection Of

Detection of prostate cancer (PCa) and distinguishing indolent versus aggressive forms of the disease is a critical clinical challenge. The current clinical test is circulating prostate-specific antigen levels, which faces particular challenges in cancer diagnosis in the range of 4 to 10 ng/mL. Thus, a concerted effort toward building a noninvasive biomarker panel has developed. In this report, the hypothesis that nuclear magnetic resonance (NMR)-derived metabolomic profiles measured in the urine of biopsy-negative versus biopsy-positive individuals would nominate a selection of potential biomarker signals was investigated. 1H NMR spectra of urine samples from 317 individuals (111 biopsy-negative, 206 biopsy-positive) were analyzed. A double cross-validation partial least squares-discriminant analysis modeling technique was utilized to nominate signals capable of distinguishing the two classes. It was observed that after variable selection protocols were applied, a subset of 29 variables produced an area under the curve (AUC) value of 0.94 after logistic regression analysis, whereas a “master list” of 18 variables produced a receiver operating characteristic ROC) AUC of 0.80. As proof of principle, this study demonstrates the utility of NMR-based metabolomic profiling of urine biospecimens in the nomination of PCa-specific biomarker signals and suggests that further investigation is certainly warranted.

Sign in / Sign up

Export Citation Format

Share Document